淋巴结降期与手术方式及非小细胞肺癌术后长期生存的关系
RATS与VATS淋巴结降期率低于OPEN,且未转化为生存优势;RATS在淋巴结检出或降期方面不优于VATS。
要点
- RATS与VATS淋巴结降期率低于OPEN,但更高降期率未带来生存获益。
- 全分期中RATS与VATS总生存优于OPEN(HR均0.89,P<0.01)。
- I期患者仅VATS与总生存改善相关(HR=0.81,P<0.01),RATS无此关联。
核心结论
- RATS肺叶切除术在淋巴结检出数量或NSCLC降期方面不优于VATS肺叶切除术。
- OPEN更高的淋巴结降期率未在任何NSCLC分期中带来生存优势,且可能与总生存下降相关。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库2010至2014年接受肺叶切除术且未行新辅助治疗的NSCLC患者。
主要发现
- 三组平均检出淋巴结数分别为10.9、11.3和10(P<0.01),降期率分别为11.2%、11.7%和12.6%(P<0.01)。
- 全分期多变量分析显示RATS和VATS与OPEN相比总生存改善(HR均=0.89;P<0.01)。
- I期疾病中,VATS而非RATS与OPEN相比与总生存增加相关(HR=0.81;P<0.01)。
临床怎么用
- 选择RATS或VATS肺叶切除术时,不应以淋巴结降期率更高作为肿瘤学优势理由。
- OPEN淋巴结降期率较高但未改善生存,临床决策需综合评估手术方式对长期生存的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Proponents of open thoracotomy (OPEN) and robot-assisted thoracic surgery (RATS) claim its oncological superiority over video-assisted thoracic surgery (VATS) in terms of the accuracy of lymph node staging. METHODS: The National Cancer Database was queried for patients with non-small-cell lung cancer (NSCLC) undergoing lobectomy without neoadjuvant therapy from 2010 to 2014. Nodal upstaging rates were compared using a surgical approach. Overall survival adjusted for confounding variables was examined using the Cox proportional hazards model. RESULTS: A total of 64 676 patients fulfilled the selection criteria. The number of patients who underwent lobectomy by RATS, VATS and OPEN approaches was 5470 (8.5%), 17 545 (27.1%) and 41 661 (64.4%), respectively. The mean number of lymph nodes examined for each of these approaches was 10.9, 11.3 and 10 (P < 0.01) and upstaging rates were 11.2%, 11.7% and 12.6% (P < 0.01), respectively. For patients with clinical stage I disease (N = 46 826; RATS = 4338, VATS = 13 416 and OPEN = 29 072), the mean lymph nodes examined were 10.6, 10.8 and 9.4 (P < 0.01), and upstaging rates were 10.8%, 11.1% and 12.1% (P < 0.01), respectively. A multivariable analysis suggested an association with improved survival with RATS and VATS compared with OPEN surgery [hazard ratio (HR) = 0.89 and 0.89, respectively; P < 0.01] for patients with all stages. In stage I disease, VATS but not RATS was associated with increased overall survival compared with the OPEN approach (HR = 0.81; P < 0.01). CONCLUSIONS: RATS lobectomy is not superior to VATS lobectomy with respect to lymph node yield or upstaging of NSCLC. Increased nodal upstaging by the OPEN approach does not confer a survival advantage in any stage of NSCLC and may be associated with decreased overall survival.
引用
- Hennon MW, DeGraaff LH, Groman A, et al. The association of nodal upstaging with surgical approach and its impact on long-term survival after resection of non-small-cell lung cancer. Eur J Cardiothorac Surg. 2020. PMID: 31764992. doi:10.1093/ejcts/ezz320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。